Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Treatment
Share your love
Verana Health Launches Qdata Module for TED Research
Verana Health has introduced its Qdata Thyroid Eye Disease (TED) module, a new addition to its suite of data solutions, featuring a comprehensive dataset derived from over 250,000 de-identified patients. This module is designed to enhance the extraction of diagnoses…
SalioGen Picks SGT-1001 for Stargardt Disease Development
SalioGen Therapeutics announced the selection of SGT-1001 as a development candidate for Stargardt disease treatment, a rare inherited retinal disease. This innovative therapy, SGT-1001, is designed as a one-time, non-viral intervention aimed at slowing or halting the progressive central vision…
Ocugen Completes Dosing in Key Trial for GA Treatment
Ocugen has officially completed dosing in the second cohort of its phase 1/2 ArMaDa trial of OCU410, a novel gene therapy designed to treat geographic atrophy (GA). The therapy, known as adeno-associated viral vector 5 human RORA (AAV5-hRORA), is being…
10 Organizations Making a Difference in Eye Health
In the vast and complex world of healthcare, eye health often doesn’t receive as much attention as it should, despite being crucial to our quality of life. Vision problems and blindness significantly affect millions of people globally, hindering education, employment,…
New Treatment Slows Down Progression of AMD, RP
A breakthrough study has unveiled a promising advancement in the treatment of incurable eye diseases such as age-related macular degeneration and retinitis pigmentosa. Researchers have successfully integrated anti-inflammatory drugs into a hydrogel, aiming to combat inflammation in the retina while…
Researchers Find Genetic Targets for Strabismus Treatment
Researchers at Boston Children’s Hospital have made a significant advancement in understanding the genetic components of strabismus, a common eye condition that causes misalignment of the eyes, specifically esotropia (eyes turning inward) and exotropia (eyes turning outward). They discovered chromosomal…
Ocular Therapeutix Reports Promising Axpaxli Results in DR Study
Ocular Therapeutix announced positive topline results from its phase 1 HELIOS study, which evaluated the safety, tolerability, and efficacy of Axpaxli versus a sham control in patients with moderately severe to severe nonproliferative diabetic retinopathy (NPDR) without diabetic macular edema…
Eye Health Initiative Overcomes Access Barriers in Malawi
In an inspiring leap towards health equity, a new eye health project in Malawi has successfully brought essential services to the grassroots level. This initiative, supported by Sightsavers, has notably reached over 122,000 individuals in rural and economically disadvantaged areas…
Caplin Granted USFDA Approval for Key Ophthalmic Solution
Caplin Steriles Limited (Caplin), a subsidiary of Caplin Point Laboratories Limited, has received final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Ketorolac Tromethamine Ophthalmic Solution 0.5%. This product is…
Pravin U. Dugel Becomes President & CEO at Ocular Therapeutix
Ocular Therapeutix announced a significant shift in its leadership structure, as Executive Chairman, Pravin U. Dugel, MD, will now also take on the roles of President and Chief Executive Officer. Dr. Dugel will continue his duties as a director and…